| Progressive Home Care - Auburn | |
| 11879 Kemper Road, Suite 15, Auburn, California 95603 | |
| (530) 823-3896 | |
| Name | Progressive Home Care - Auburn |
|---|---|
| Location | 11879 Kemper Road, Suite 15, Auburn, California |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 557482 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 94947, 95521, 95602, 95603, 95604, 95606, 95608, 95610, 95613, 95614, 95619, 95621, 95623, 95624, 95626, 95628, 95630, 95631, 95633, 95634, 95635, 95641, 95648, 95650, 95652, 95655, 95658, 95660, 95661, 95662, 95663, 95664, 95667, 95670, 95672, 95673, 95677, 95678, 95680, 95681, 95682, 95701, 95703, 95712, 95713, 95714, 95717, 95722, 95736, 95742, 95746, 95747, 95762, 95763, 95765, 95811, 95814, 95815, 95816, 95817, 95818, 95819, 95820, 95821, 95822, 95823, 95824, 95825, 95826, 95827, 95828, 95831, 95832, 95833, 95834, 95835, 95838, 95841, 95842, 95843, 95864, 95865, 95924, 95945, 95946, 95948, 95949, 95959, 95960, 95965, 95975, 95977 |
| NPI Number | 1396770269 |
| Organization Name | GRANITE POINT PARTNERS LLC |
| Doing Business As | PROGRESSIVE HOME CARE - AUBURN |
| Address | 11879 Kemper Rd, Suite 15, Auburn, CA 95603 |
| Phone Number | 530-823-3896 |
News Archive
EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
Mary Ann Liebert, Inc., publishers announces the launch of 3D Printing and Additive Manufacturing, a highly innovative, peer-reviewed journal on this rapidly growing disruptive technology.
In most people, high blood levels of the fat known as triglycerides are an early warning sign of type 2 diabetes and metabolic syndrome, but in people of African descent these dangerous health conditions may go undiagnosed because triglyceride levels are not at the level used to diagnose metabolic syndrome (>150 mg/dL). This is known as the "TG (or lipid) paradox."
› Verified 1 days ago
| Quality Rating: |
News Archive
EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
Mary Ann Liebert, Inc., publishers announces the launch of 3D Printing and Additive Manufacturing, a highly innovative, peer-reviewed journal on this rapidly growing disruptive technology.
In most people, high blood levels of the fat known as triglycerides are an early warning sign of type 2 diabetes and metabolic syndrome, but in people of African descent these dangerous health conditions may go undiagnosed because triglyceride levels are not at the level used to diagnose metabolic syndrome (>150 mg/dL). This is known as the "TG (or lipid) paradox."
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 97 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.7 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.8 | 99.6 |
| How often the home health team checked patients for depression | 99 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 86.5 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 92.4 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 97.5 | 96.4 |
News Archive
EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
Mary Ann Liebert, Inc., publishers announces the launch of 3D Printing and Additive Manufacturing, a highly innovative, peer-reviewed journal on this rapidly growing disruptive technology.
In most people, high blood levels of the fat known as triglycerides are an early warning sign of type 2 diabetes and metabolic syndrome, but in people of African descent these dangerous health conditions may go undiagnosed because triglyceride levels are not at the level used to diagnose metabolic syndrome (>150 mg/dL). This is known as the "TG (or lipid) paradox."
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 76.3 | 79.6 |
| How often patients got better at getting in and out of bed | 85.1 | 81.1 |
| How often patients got better at bathing | 79.6 | 82.3 |
| How often patients’ breathing improved | 84.9 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 94.4 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 67.3 | 75 |
| How often home health patients had to be admitted to the hospital | 12.6 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 15.6 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 95.9 | 94 |
News Archive
EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
Mary Ann Liebert, Inc., publishers announces the launch of 3D Printing and Additive Manufacturing, a highly innovative, peer-reviewed journal on this rapidly growing disruptive technology.
In most people, high blood levels of the fat known as triglycerides are an early warning sign of type 2 diabetes and metabolic syndrome, but in people of African descent these dangerous health conditions may go undiagnosed because triglyceride levels are not at the level used to diagnose metabolic syndrome (>150 mg/dL). This is known as the "TG (or lipid) paradox."
› Verified 1 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
Mary Ann Liebert, Inc., publishers announces the launch of 3D Printing and Additive Manufacturing, a highly innovative, peer-reviewed journal on this rapidly growing disruptive technology.
In most people, high blood levels of the fat known as triglycerides are an early warning sign of type 2 diabetes and metabolic syndrome, but in people of African descent these dangerous health conditions may go undiagnosed because triglyceride levels are not at the level used to diagnose metabolic syndrome (>150 mg/dL). This is known as the "TG (or lipid) paradox."
› Verified 1 days ago
The patient survey data of Progressive Home Care - Auburn is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 89 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 86 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 87 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 85 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 79 | 78 |
News Archive
EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
Mary Ann Liebert, Inc., publishers announces the launch of 3D Printing and Additive Manufacturing, a highly innovative, peer-reviewed journal on this rapidly growing disruptive technology.
In most people, high blood levels of the fat known as triglycerides are an early warning sign of type 2 diabetes and metabolic syndrome, but in people of African descent these dangerous health conditions may go undiagnosed because triglyceride levels are not at the level used to diagnose metabolic syndrome (>150 mg/dL). This is known as the "TG (or lipid) paradox."
› Verified 1 days ago
Sutter Auburn Faith Vna & Hospice Location: 11775 Education Street, Suite 201, Auburn, California 95602 Ratings: Phone: (530) 886-6650 | |
Progressive Home Care - Auburn Location: 11879 Kemper Road, Suite 15, Auburn, California 95603 Ratings: Phone: (530) 823-3896 |